The rise in cancer prevention in developed nations and governments' conscious efforts to promote early diagnosis and treatment have boosted the global market for biosimilar G-CSF sales. The market will experience significant growth as a result of the approved biosimilars Grafeel, Colstim, Neukine, and Filcad, which are also affordable and easily accessible in developing nations. The number of cancer patients is rising in China and India, which is likely to expand the global market. Therefore, using biosimilars rather than the original biologics helps patients pay less for healthcare, which raises demand in the global G-CSF biosimilars sales market. The prices of individual biosimilars are higher than those of generic drugs because of the intricate biological manufacturing processes used to create them.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-g-csf-peg-g-csf-market
Data Bridge Market Research analyses that the G-CSF PEG-G-CSF Market is expected to reach the value of USD 5,685.40 million by 2030, from USD 3,736.34 million in 2022 at a CAGR of 5.5% during the forecast period from 2023 to 2030. Chemotherapy often leads to a decline in white blood cell count, resulting in neutropenia. G-CSF and PEG-G-CSF are commonly used to stimulate the production of neutrophils and reduce the risk of infections in cancer patients undergoing chemotherapy. As the incidence of cancer continues to rise globally, the demand for G-CSF and PEG-G-CSF is expected to increase.
Key Findings of the Study
Increasing incidence of neutropenia is expected to drive the market's growth rate
The increasing incidence of neutropenia, a condition marked by low neutrophil levels, is a significant driver for the G-CSF (Granulocyte Colony-Stimulating Factor) and PEG-G-CSF (Pegylated Granulocyte Colony-Stimulating Factor) market. Neutropenia commonly occurs as a side effect of chemotherapy and certain diseases, necessitating treatments to stimulate the production of white blood cells. G-CSF and PEG-G-CSF are used in such cases to enhance the body's ability to produce neutrophils, leading to a higher demand for these medications.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Indication (Neutropenia, Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Harmony Deficiency, and Others), Dosage (Mono and Combination), Route Of Administration (Intravenous, Subcutaneous), Packaging (Single Use Vials and Pre Filled Syringes), End User (Hospitals and Clinics, Research and Academic Institutes, Ambulatory Surgical Centers and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
Market Players Covered
|
USV Private Limited (India), Viatris Inc. (U.S.), Biocon (India), Fresenius Kabi AG (Germany), Hangzhou Jiuyuan Gene Engineering Co., Ltd. (China), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Apotex Inc. (Canada), Cadila Pharmaceuticals (India), Dr. Reddy’s Laboratories Ltd. (India), Amneal Pharmaceuticals LLC. (U.S.), Coherus BioSciences (U.S.), Accord Healthcare (U.K.), NAPP PHARMACEUTICALS LIMITED. (U.K.), Intas Pharmaceuticals Ltd. (India), Mundipharma International (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Spectrum Pharmaceuticals, Inc. (U.S.), Kyowa Kirin Co., Ltd. (Japan), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The G-CSF PEG-G-CSF market is segmented on the basis of indication, dosage, route of administration, packaging, end user, and distribution channel
- On the basis of indication, the global G-CSF / PEG-G-CSF market is segmented into neutropenia, oncology, chronic and autoimmune disease, blood disorders, growth hormone deficiency and others. In 2023, neutrpenia segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.7% in the forecast period of 2023 to 2030 due to its prevalence in various conditions, including cancer treatments, chemotherapy, and autoimmune diseases. The need for effective treatments to manage low neutrophil levels drives the demand for therapies targeting Neutropenia.
- On the basis of dosage, the global G-CSF / PEG-G-CSF market is segmented into mono and combination. In 2023, the mono segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.3% in the forecast period of 2023 to 2030 due to the maximum number of cancer treatment drugs are comes in mono dosage form only.
In 2023, the mono segment is expected to dominate the dosage segment of the global G-CSF / PEG-G-CSF market
In 2023, the mono segment is expected to dominate the global G-CSF / PEG-G-CSF market owing to the specific condition or symptom. For instance, if a patient is prescribed a mono dosage of a painkiller such as acetaminophen, they would receive a specific amount of acetaminophen without any other active ingredients with a CAGR of 5.3% in the forecast period of 2023 to 2030
- On the basis of route of administration, the global G-CSF / PEG-G-CSF market is segmented into intravenoue, subcutanious and intraperitoneal. In 2023, subcutanious segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.4% in the forecast period of 2023 to 2030 due to the increasing use of subcuetanious injection and self-administration by the patient, shorter time of application process with less infusion related adverse events and consequently lower healthcare costs.
- On the basis of packaging, the global G-CSF / PEG-G-CSF market is segmented into single-use vials and pre filled syringes. In 2023, pre filled syringes segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.4% in the forecast period of 2023 to 2030 due to their convenience, safety, and accuracy in delivering medications. They offer ready-to-use dosages, reduce the risk of contamination, and improve patient compliance, making them preferred choices in healthcare settings.
In 2023, the prefilled syringes segment is expected to dominate the packaging segment of the global G-CSF / PEG-G-CSF market
In 2023, the pre filled syringes segment is expected to dominate the global G-CSF / PEG-G-CSF market owing to their convenience, safety, and accuracy in delivering medications. They offer ready-to-use dosages, reduce the risk of contamination, and improve patient compliance, making them preferred choices in healthcare settings with a CAGR of 5.4% in the forecast period of 2023 to 2030
- On the basis of end user, the global G-CSF / PEG-G-CSF market is segmented into hospitals and clinics, research and academic institute, ambulatory surgical centers and others. In 2023, hospitals and clinics segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.7% in the forecast period of 2023 to 2030 due to Cancer care is complex and requires skilled and accountable leadership and management at all levels so people prefer hospital and clinics.
- 유통 채널을 기준으로 글로벌 G-CSF/PEG-G-CSF 시장은 병원 약국, 온라인 약국, 그리고 소매 약국으로 구분됩니다. 2023년에는 병원 약국 부문이 약물 처방 및 투여 결정에 대한 의사의 참여가 증가하고, 응급 상황 시 병원 약국의 편의성이 높아져 2023년부터 2030년까지 연평균 성장률 5.9%로 글로벌 G-CSF/PEG-G-CSF 시장을 주도할 것으로 예상됩니다.
주요 플레이어
Data Bridge Market Research는 G-CSF PEG-G-CSF 시장의 주요 G-CSF PEG-G-CSF 시장 참여자로 다음 회사를 인식합니다. USV Private Limited(인도), Viatris Inc.(미국), Biocon(인도), Fresenius Kabi AG(독일), Hangzhou Jiuyuan Gene Engineering Co., Ltd.(중국), Amgen Inc.(미국), Pfizer Inc.(미국), Sandoz International GmbH(독일), Apotex Inc.(캐나다), Cadila Pharmaceuticals(인도)
시장 개발
- 2022년 미국 식품의약국(FDA)은 카시브 바이오사이언스(Kashiv Biosciences)의 뉴포젠(Neupogen) 바이오시밀러인 필그라스팀-아요우(filgrastim-ayow)에 대한 생물의약품 허가 신청(BLA)을 승인했습니다. 이 제품은 렐루코(RELEUKO)라는 상표명으로 판매됩니다.
- 2022년, Amgen과 Generate Biomedicines는 다양한 치료 영역과 경로에 걸쳐 5가지 임상 표적에 대한 단백질 치료제를 발견하고 개발하기 위한 연구 협력 계약을 발표했습니다.
- 특허 만료(제네릭 및 바이오시밀러) 의약품 분야의 글로벌 선두 기업인 Sandoz는 2022년에 자사의 바이오시밀러 파이프라인에 대한 추가 진전을 발표했으며, 제안된 바이오시밀러인 denosumab에 대한 통합 ROSALIA 1/3상 임상 시험 연구에서 긍정적인 결과가 발표되었습니다.
지역 분석
지리적으로 G-CSF PEG-G-CSF 시장 보고서에서 다루는 국가는 북미의 미국, 캐나다 및 멕시코, 유럽의 독일, 프랑스, 영국, 네덜란드, 스위스, 벨기에, 러시아, 이탈리아, 스페인, 터키, 유럽의 기타 유럽, 중국, 일본, 인도, 한국, 싱가포르, 말레이시아, 호주, 태국, 인도네시아, 필리핀, 아시아 태평양(APAC)의 기타 아시아 태평양(APAC), 사우디 아라비아, UAE, 남아프리카 공화국, 이집트, 이스라엘, 중동 및 아프리카(MEA)의 일부인 기타 중동 및 아프리카(MEA), 남미의 일부인 기타 남미입니다.
Data Bridge Market Research 분석에 따르면:
유럽은 2023-2030년 예측 기간 동안 G-CSF PEG-G-CSF 시장 에서 지배적인 지역입니다 .
유럽이 G-CSF 및 PEG-G-CSF 시장에서 우위를 점하는 것은 주요 시장 참여자들의 존재와 높은 GDP 규모를 자랑하는 역내 최대 소비 시장 덕분입니다. 유럽에는 시장에서 탄탄한 입지를 구축한 여러 유수 제약 회사가 있습니다. 또한, 이 지역의 우수한 의료 인프라, 유리한 보험급여 정책, 그리고 첨단 의료 기술에 대한 집중은 유럽이 업계를 선도하는 데 기여하며 시장 성장과 혁신을 주도하고 있습니다.
북미는 2023-2030년 예측 기간 동안 G-CSF PEG-G-CSF 시장에서 가장 빠르게 성장하는 지역으로 추정됩니다.
북미는 G-CSF 및 PEG-G-CSF 시장에서 가장 빠르게 성장하는 지역으로 예상됩니다. 미국은 기술 발전과 지속적인 혁신을 통해 G-CSF 및 PEG-G-CSF 시장의 성장을 경험할 것으로 예상되기 때문입니다. 미국은 최첨단 연구 시설, 임상시험, 그리고 신약 개발의 최전선에 있는 제약 회사들을 포함한 탄탄한 의료 생태계를 갖추고 있습니다. 첨단 의료 기술과 연구 개발에 중점을 둔 미국은 최신 기술 발전과 발명을 통해 G-CSF 및 PEG-G-CSF 시장의 성장을 주도할 수 있는 유리한 입지를 갖추고 있습니다.
G-CSF PEG-G-CSF 시장 보고서 에 대한 자세한 내용은 여기를 클릭하세요. – https://www.databridgemarketresearch.com/reports/global-g-csf-peg-g-csf-market
